Biochemical Marker Panel for Cardiovascular Mortality Risk Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing cardiovascular mortality in diabetic subjects lack effective biochemical markers to predict increased risk, particularly for fatal myocardial infarction, fatal stroke, and heart failure, with existing markers providing limited accuracy and specificity.
Innovation Solution
The use of a panel of biochemical markers including alpha-Glutathione-S-Transferase, Trefoil Factor 3, alpha-2-Macroglobulin, Macrophage-derived Chemokine, Apolipoprotein B, Selenoprotein P, Tenascin C, and Hepatocyte Growth Factor Receptor, either alone or in combination with known markers like Nt-pro BNP, Angiopoietin-2, and others, to assess cardiovascular mortality risk in diabetic subjects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional markers (NT-pro BNP, hs-cTnT) are used to assess cardiovascular mortality risk, then some predictive capability is achieved, but accuracy and specificity remain limited
Solution Approach 1:
The patent combines multiple biochemical markers (alpha-Glutathione-S-Transferase, Trefoil Factor 3, alpha-2-Macroglobulin, Macrophage-derived Chemokine, Apolipoprotein B, Selenoprotein P, Tenascin C, Hepatocyte Growth Factor Receptor) with conventional markers (NT-pro BNP, Angiopoietin-2, Growth Differentiation Factor 15, Peroxiredoxin-4, YKL-40, Insulin-like Growth Factor Binding Protein 2, Osteoprotegerin, Chromogranin A) into a comprehensive panel. This merging of marker systems achieves superior accuracy and specificity in predicting cardiovascular mortality by capturing multiple pathological pathways simultaneously, resolving the contradiction between predictive capability and diagnostic precision.
2Measurement precision
If a panel of multiple biochemical markers is used, then accuracy and specificity of mortality prediction improve, but device complexity and cost increase
Solution Approach 1:
The patent segments the comprehensive marker panel into distinct groups: first markers (alpha-Glutathione-S-Transferase, Trefoil Factor 3, alpha-2-Macroglobulin, Macrophage-derived Chemokine) and further markers (Nt-pro BNP, Angiopoietin-2, Growth Differentiation Factor 15, Peroxiredoxin-4, YKL-40, Insulin-like Growth Factor Binding Protein 2, Osteoprotegerin, Chromogranin A). This segmentation allows for systematic evaluation and prioritization of markers based on their prognostic value, making the complex assessment manageable while maintaining high predictive accuracy.
3Loss of information
If existing risk markers are used, then basic mortality assessment is possible, but incremental prognostic information is insufficient
Solution Approach 1:
The patent introduces intermediary markers that bridge conventional risk assessment and detailed pathological mechanisms. Markers such as alpha-Glutathione-S-Transferase (reflecting oxidative stress and drug metabolism), Trefoil Factor 3 (indicating gastrointestinal mucosal integrity), and Macrophage-derived Chemokine (signaling inflammation) serve as intermediaries that provide incremental prognostic information while maintaining compatibility with conventional risk markers, thereby enhancing overall risk assessment precision without losing connection to established clinical parameters.
Data Source
Figure 1
AI summary
The present invention relates to methods for assessing an increased risk for mortality comprising the determination of biochemical markers. It also relates to the use of the biochemical markers or marker panels for the assessment of an increased risk for mortality and to kits for performing the methods of the invention as well as to the therapeutic use of insulin analogues for reducing morality.